Navigation Links
Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma
Date:5/20/2008

tructures. All Synta drug candidates were invented by Synta scientists using our compound library and drug discovery capabilities. Synta has a partnership with GlaxoSmithKline for the joint development and commercialization of its lead investigational drug candidate, elesclomol, which is in a global, pivotal Phase III clinical trial for the treatment of metastatic melanoma. For more information, please visit http://www.syntapharma.com.

GlaxoSmithKline Cautionary Statement Regarding Forward-Looking Statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK's operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2007.

Synta Pharmaceuticals Corp. Safe Harbor Statement

This media release may contain forward-looking statements about Synta Pharmaceuticals Corp. Such forward-looking statements can be identified by the use of forward-looking terminology such as "will", "would", "should", "expects", "anticipates", "intends", "plans", "believes", "may", "estimates", "predicts", "projects", or similar expressions intended to identify forward-looking statements. Such statements, including statements relating to the timing and progress of our clinical and preclinical programs, reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including those described in "Risk Factors" of our Form 10-K for the year ended December 31, 2007 as filed
'/>"/>

SOURCE GlaxoSmithKline; Synta Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994
2. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
3. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
4. Pivotal Study Shows Physician/Nurse Teams Using SEDASYS(TM) System Reduced Risk of Over Sedation With Propofol
5. Amikacin Inhale Shows Promising Results in Phase II Study
6. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
7. Infant Vaccines Produce Autism Symptoms in New Primate Study by University of Pittsburgh Scientists
8. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
9. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
10. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
11. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)...  Mallinckrodt plc (NYSE: MNK ) announced today ... repurchase program. The open-ended authorization permits the company to ... shares. "Funding additional initiatives and seeking ... continue to pursue a range of focused growth strategies," ...
(Date:1/22/2015)... 2015  ViewRay™, a privately held medical device company, announced ... agreement with ITOCHU Corporation (Tokyo Stock Exchange TYO: 8001) ... treatment of cancer in Japan . ... first and only MRI-guided radiation therapy system that images ...
(Date:1/22/2015)... 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the ... therapies for cardiovascular disease and overall health is pleased to ... 2014 and its outlook for 2015 from the CEO, Mr. ... We would like to take this opportunity to share ...
Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... Concentric Medical,Inc., the global leader in devices for ... results of its Multi MERCI trial will be,published in ... The,Multi MERCI trial was the second trial studying safety ... that is delivered,into the brain and is designed to ...
... ... investigator interest, SEATTLE, March 6 ... that its investigational drug,pixantrone will be studied in a multicenter ... Belgium, which sponsors a,consortium of centers involved in studying new ...
Cached Medicine Technology:Multi Merci Trial Results Published in Peer Reviewed Journal 2Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis 2Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis 3Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis 4
(Date:1/22/2015)... Hawley, PA (PRWEB) January 22, 2015 Woodloch ... Pocono Mountains, has been selected by TripAdvisor as the number ... and the 6th best in the world for their annual ... online travel community . The website is home to ...
(Date:1/22/2015)... a seasoned and trusted leader who consistently delivers trendy dresses ... it lead the wedding dress industry into the future. Today, ... the global market. , “The CEO of VogueQueen is uniquely ... continuing the goal of operational excellence and giving back to ...
(Date:1/22/2015)... 2015 Blue Cross and Blue Shield of ... what it means to “Live Fearless.” , The ... share their stories about how they or someone they know ... by living in the moment. By telling these types of ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and David Leadbetter ... to bestow a Juvent Sports Achievement award upon an ... The award commemorated and congratulated McKitrick for her record ... her first amateur tournament in 1979 and most recently ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Autocarinsurancebest.com has released ... purchasing a commercial auto insurance policy . , Auto ... their vehicles. It is no longer necessary to call an ... are now available online on a single website: http://autocarinsurancebest.com/ ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Commercial Auto Insurance Provides Several Important Features! 2
... News) -- Rheumatoid arthritis patients who believe in their ... -- are more likely to reach those objectives, researchers ... who achieve their physical activity goals have lower levels ... Researchers in the Netherlands conducted an initial assessment ...
... faculty researchers and clinicians with expertise in polypharmacy, ... geriatric researcher at a free conference examining Alzheimer,s ... Medicine and Nursing join with the Greater Kentucky ... to present "The Journey: Alzheimer,s Disease and Caregiving" ...
... 2011) Bone marrow transplantation with genetically modified cells ... study led by Dr. Vivek Rangnekar, associate director of ... University of Kentucky. Bone marrow, a spongy tissue ... including leukocytes, erythrocytes and platelets. In the cover story ...
... , WEDNESDAY, Aug. 24 (HealthDay News) -- High ... fatal abnormal heart rhythms and should no longer be ... said Wednesday. Doses of Celexa (citalopram hydrobromide) greater ... the electrical activity of the heart, which can lead ...
... Aug. 24 (HealthDay News) -- U.S. teens who use social networking ... drugs and alcohol than teens with little exposure to such media, ... youths from around the nation aged 12 to 17 and about ... of teens said they used social networking sites. Social network ...
... Ont., Aug 24, 2011 More than eight out of ... and elsewhere have at least one chronic health condition and ... who are "vulnerably housed"meaning they live in unsafe, unstable or ... the survey found. The underlying cause for these health ...
Cached Medicine News:Health News:UofL experts featured at free Alzheimer's disease conference Sept. 17 2Health News:Teen Drinking, Smoking Higher Among Facebook Users: Survey 2Health News:Teen Drinking, Smoking Higher Among Facebook Users: Survey 3Health News:Study: 85 percent of homeless people have chronic health conditions 2
Detection of Lupus Anticoagulants. Freeze-dried hexagonal phase phos-phatidylethanolamine; normal plasma with heparin inhibitor; PTT-LS reagent of cephalin and particulate siliceous activator;all fre...
Colorimetric Assay of Protein C Activity by STA© Analyzers. Highly purified extract of Agkistrodon c. contortrix venom for specific activation of protein C, with an activator selected specially ...
Immuno-turbidimetric assay for Free Protein Sby STA© Analyzers. Suspension of microparticles coated with monoclonal antibodies to Free Protein S....
Substrate Plasma for Factor V Assay by STA© Analyzers. Freeze-dried human plasma, artificially depleted of factor V....
Medicine Products: